Related Experiment Video

Updated: May 16, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer

Jinyong Kim1, Sehhoon Park1, Bo Mi Ku2

  • 1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea.

Cancer
|April 2, 2025
PubMed

Insights

This review details advances in treating non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Precision medicine and overcoming resistance are key to optimizing outcomes for EGFR-mutated NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations presents unique treatment challenges.
  • First-generation EGFR tyrosine kinase inhibitors (TKIs) demonstrated initial efficacy, driving the field of precision oncology.

Purpose of the Study:

  • To provide a comprehensive update on current and emerging treatments for EGFR-mutated NSCLC.
  • To highlight strategies for overcoming acquired resistance to EGFR-targeted therapies.
  • To discuss the role of EGFR TKIs in various stages of NSCLC.

Main Methods:

  • Review of current literature on EGFR-mutated NSCLC treatment.
  • Analysis of advances in precision medicine and targeted therapies.
  • Examination of resistance mechanisms and novel therapeutic approaches.

Main Results:

  • Third-generation EGFR TKIs are the current first-line standard of care for advanced NSCLC.
  • Combinations of third-generation EGFR TKIs with chemotherapy or amivantamab show improved progression-free survival.
  • EGFR TKIs are being explored in perioperative and neoadjuvant settings for early-stage NSCLC.

Conclusions:

  • Acquired resistance to EGFR TKIs is complex and heterogeneous, necessitating personalized treatment strategies.
  • The treatment landscape for EGFR-mutated NSCLC is dynamic, requiring continuous adaptation of therapeutic approaches.
  • Optimizing patient outcomes hinges on tailored strategies addressing individual resistance mechanisms.
Keywords:
epidermal growth factor receptor (EGFR)non–small cell lung cancer (NSCLC)resistancetyrosine kinase inhibitor (TKI)

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

990

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
110
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K